Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Androgen receptor plasticity and its implications for prostate cancer therapy.

Snow O, Lallous N, Singh K, Lack N, Rennie P, Cherkasov A.

Cancer Treat Rev. 2019 Dec;81:101871. doi: 10.1016/j.ctrv.2019.05.001. Epub 2019 Jun 11. Review.

PMID:
31698174
2.

Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer.

Pällmann N, Livgård M, Tesikova M, Zeynep Nenseth H, Akkus E, Sikkeland J, Jin Y, Koc D, Kuzu OF, Pradhan M, Danielsen HE, Kahraman N, Mokhlis HM, Ozpolat B, Banerjee PP, Uren A, Fazli L, Rennie PS, Jin Y, Saatcioglu F.

Oncogene. 2019 Aug;38(35):6301-6318. doi: 10.1038/s41388-019-0879-2. Epub 2019 Jul 16.

PMID:
31312022
3.

UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells.

Samudio I, Hofs E, Cho B, Li M, Bolduc K, Bu L, Liu G, Lam V, Rennie P, Jia W, Elisia I, Krystal G.

J Immunother. 2019 Jun;42(5):162-174. doi: 10.1097/CJI.0000000000000261.

PMID:
30933043
4.

ETS transcription factors as emerging drug targets in cancer.

Hsing M, Wang Y, Rennie PS, Cox ME, Cherkasov A.

Med Res Rev. 2019 Mar 29. doi: 10.1002/med.21575. [Epub ahead of print] Review.

PMID:
30927317
5.

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer.

Carabet LA, Leblanc E, Lallous N, Morin H, Ghaidi F, Lee J, Rennie PS, Cherkasov A.

Molecules. 2019 Feb 20;24(4). pii: E763. doi: 10.3390/molecules24040763.

6.

IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, Danielsen H, Theis F, Patterson JB, Jin Y, Saatcioglu F.

Nat Commun. 2019 Jan 24;10(1):323. doi: 10.1038/s41467-018-08152-3.

7.

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.

Carabet LA, Rennie PS, Cherkasov A.

Int J Mol Sci. 2018 Dec 29;20(1). pii: E120. doi: 10.3390/ijms20010120. Review.

8.

Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor.

Dueva E, Singh K, Kalyta A, LeBlanc E, Rennie PS, Cherkasov A.

Molecules. 2018 Nov 14;23(11). pii: E2967. doi: 10.3390/molecules23112967.

9.

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.

Carabet LA, Lallous N, Leblanc E, Ban F, Morin H, Lawn S, Ghaidi F, Lee J, Mills IG, Gleave ME, Rennie PS, Cherkasov A.

Eur J Med Chem. 2018 Dec 5;160:108-119. doi: 10.1016/j.ejmech.2018.09.023. Epub 2018 Sep 11.

PMID:
30326371
10.

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

Dalal K, Morin H, Ban F, Shepherd A, Fernandez M, Tam KJ, Li H, LeBlanc E, Lack N, Prinz H, Rennie PS, Cherkasov A.

Eur J Med Chem. 2018 Sep 5;157:1164-1173. doi: 10.1016/j.ejmech.2018.08.059. Epub 2018 Aug 24.

PMID:
30193215
11.

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, Shepherd A, Sharma A, Peacock J, Carlson ML, LeBlanc E, Perez C, Duong F, Ong CJ, Rennie PS, Cherkasov A.

Cancer Lett. 2018 Nov 28;437:35-43. doi: 10.1016/j.canlet.2018.08.016. Epub 2018 Aug 27.

PMID:
30165195
12.

Toxic Colors: The Use of Deep Learning for Predicting Toxicity of Compounds Merely from Their Graphic Images.

Fernandez M, Ban F, Woo G, Hsing M, Yamazaki T, LeBlanc E, Rennie PS, Welch WJ, Cherkasov A.

J Chem Inf Model. 2018 Aug 27;58(8):1533-1543. doi: 10.1021/acs.jcim.8b00338. Epub 2018 Aug 15.

PMID:
30063345
13.

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors.

Ben-Eltriki M, Deb S, Hassona M, Meckling G, Fazli L, Chin MY, Lallous N, Yamazaki T, Jia W, Rennie PS, Cherkasov A, Tomlinson Guns ES.

Oncotarget. 2018 Apr 20;9(30):20965-20978. doi: 10.18632/oncotarget.24695. eCollection 2018 Apr 20.

14.

Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer.

Ban F, Dalal K, LeBlanc E, Morin H, Rennie PS, Cherkasov A.

Mol Inform. 2018 Sep;37(9-10):e1800043. doi: 10.1002/minf.201800043. Epub 2018 May 7. Review.

PMID:
29733509
15.

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.

Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS.

Int J Mol Sci. 2018 Feb 15;19(2). pii: E579. doi: 10.3390/ijms19020579.

16.

A TRAMP-derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti-tumor treatments.

Lardizabal J, Ding J, Delwar Z, Rennie PS, Jia W.

Prostate. 2018 May;78(6):457-468. doi: 10.1002/pros.23490. Epub 2018 Feb 16. Erratum in: Prostate. 2018 Sep;78(12):949.

PMID:
29450905
17.

Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.

Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W.

Cancer Res. 2018 Feb 1;78(3):718-730. doi: 10.1158/0008-5472.CAN-17-0599. Epub 2017 Nov 8.

18.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

19.

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T.

Nat Commun. 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y.

20.

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Dalal K, Che M, Que NS, Sharma A, Yang R, Lallous N, Borgmann H, Ozistanbullu D, Tse R, Ban F, Li H, Tam KJ, Roshan-Moniri M, LeBlanc E, Gleave ME, Gewirth DT, Dehm SM, Cherkasov A, Rennie PS.

Mol Cancer Ther. 2017 Oct;16(10):2281-2291. doi: 10.1158/1535-7163.MCT-17-0259. Epub 2017 Aug 3.

21.

Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.

Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo Y, Yamazaki T, Lawn S, Gleave ME, Gregory-Evans CY, McIntosh LP, Cox ME, Rennie PS, Cherkasov A.

Oncotarget. 2017 Jun 27;8(26):42438-42454. doi: 10.18632/oncotarget.17124.

22.

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action.

Ban F, Dalal K, Li H, LeBlanc E, Rennie PS, Cherkasov A.

J Chem Inf Model. 2017 May 22;57(5):1018-1028. doi: 10.1021/acs.jcim.7b00137. Epub 2017 May 4.

PMID:
28441481
23.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

24.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M.

Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10.

PMID:
28408175
25.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS.

J Biol Chem. 2017 Mar 10;292(10):4359. doi: 10.1074/jbc.A117.553818. No abstract available.

26.

A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo.

Lee JB, Zhang K, Tam YY, Quick J, Tam YK, Lin PJ, Chen S, Liu Y, Nair JK, Zlatev I, Rajeev KG, Manoharan M, Rennie PS, Cullis PR.

Mol Ther Nucleic Acids. 2016;5:e348. doi: 10.1038/mtna.2016.43.

27.

Correction to Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor.

Li H, Ban F, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie PS, Cherkasov A.

J Med Chem. 2017 Feb 9;60(3):1225. doi: 10.1021/acs.jmedchem.7b00005. Epub 2017 Jan 24. No abstract available.

PMID:
28118004
28.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.

29.

Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.

Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ.

Oncotarget. 2017 Feb 7;8(6):9617-9633. doi: 10.18632/oncotarget.14168.

30.

Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor.

Paul N, Carabet LA, Lallous N, Yamazaki T, Gleave ME, Rennie PS, Cherkasov A.

J Chem Inf Model. 2016 Dec 27;56(12):2507-2516. doi: 10.1021/acs.jcim.6b00400. Epub 2016 Nov 18.

PMID:
28024400
31.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7.

32.

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.

Dalal K, Munuganti R, Morin H, Lallous N, Rennie PS, Cherkasov A.

Methods Mol Biol. 2016;1443:31-54. doi: 10.1007/978-1-4939-3724-0_4.

PMID:
27246333
33.

Oncolytic virotherapy for urological cancers.

Delwar Z, Zhang K, Rennie PS, Jia W.

Nat Rev Urol. 2016 Jun;13(6):334-52. doi: 10.1038/nrurol.2016.84. Epub 2016 May 24. Review.

PMID:
27215429
34.

Tumour-specific triple-regulated oncolytic herpes virus to target glioma.

Delwar ZM, Liu G, Kuo Y, Lee C, Bu L, Rennie PS, Jia WW.

Oncotarget. 2016 May 10;7(19):28658-69. doi: 10.18632/oncotarget.8637.

35.

Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs.

Zhang KX, Matsui Y, Lee C, Osamu O, Skinner L, Wang J, So A, Rennie PS, Jia WW.

Gene Ther. 2016 May;23(5):460-8. doi: 10.1038/gt.2016.18. Epub 2016 Feb 23.

PMID:
26905370
36.

Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment.

Hosseini-Beheshti E, Choi W, Weiswald LB, Kharmate G, Ghaffari M, Roshan-Moniri M, Hassona MD, Chan L, Chin MY, Tai IT, Rennie PS, Fazli L, Tomlinson Guns ES.

Oncotarget. 2016 Mar 22;7(12):14639-58. doi: 10.18632/oncotarget.7052.

37.

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A.

Genome Biol. 2016 Jan 26;17:10. doi: 10.1186/s13059-015-0864-1.

38.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

39.

Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.

Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479.

40.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS.

J Biol Chem. 2015 Oct 23;290(43):25850. doi: 10.1074/jbc.A115.553818. No abstract available.

41.

AR-v7 protein expression is regulated by protein kinase and phosphatase.

Li Y, Xie N, Gleave ME, Rennie PS, Dong X.

Oncotarget. 2015 Oct 20;6(32):33743-54. doi: 10.18632/oncotarget.5608.

42.

Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.

Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS.

Arch Ital Urol Androl. 2015 Jul 7;87(2):121-9. doi: 10.4081/aiua.2015.2.121. Review.

43.

Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.

Barfeld SJ, Fazli L, Persson M, Marjavaara L, Urbanucci A, Kaukoniemi KM, Rennie PS, Ceder Y, Chabes A, Visakorpi T, Mills IG.

Oncotarget. 2015 May 20;6(14):12587-602.

44.

Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.

Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen H, Mills IG, Jin Y, Hotamisligil G, Saatcioglu F.

EMBO Mol Med. 2015 Jun;7(6):788-801. doi: 10.15252/emmm.201404509.

45.

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.

Singh K, Munuganti RS, Leblanc E, Lin YL, Leung E, Lallous N, Butler M, Cherkasov A, Rennie PS.

Breast Cancer Res. 2015 Feb 25;17:27. doi: 10.1186/s13058-015-0529-8.

46.

Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation.

Yu Y, Yang O, Fazli L, Rennie PS, Gleave ME, Dong X.

Prostate. 2015 Jul 1;75(10):1043-50. doi: 10.1002/pros.22988. Epub 2015 Apr 1.

PMID:
25833156
47.

STAMP2 increases oxidative stress and is critical for prostate cancer.

Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F.

EMBO Mol Med. 2015 Mar;7(3):315-31. doi: 10.15252/emmm.201404181.

48.

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A.

Chem Biol. 2014 Nov 20;21(11):1476-85. doi: 10.1016/j.chembiol.2014.09.012.

49.

Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers.

Roshan-Moniri M, Hsing M, Butler MS, Cherkasov A, Rennie PS.

Cancer Treat Rev. 2014 Dec;40(10):1137-52. doi: 10.1016/j.ctrv.2014.10.005. Review.

PMID:
25455729
50.

The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.

Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X.

Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.

Supplemental Content

Loading ...
Support Center